Electrophysiology Mapping and Ablation Devices – Market Insights – United States

The US EP mapping and ablation device market will experience strong growth through 2034, driven by the rapid expansion of AF ablation procedures and the coinciding uptake of PFA devices, which enable shorter procedure times and are supported by favorable clinical evidence.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for EP mapping and ablation devices in US from 2019 to 2034.

Rising AF ablation procedures will continue to drive growth across several segments of the EP mapping and ablation market

How have AF ablation procedure volumes shifted in the US, and what device approvals have supported growth?

What are the different levels of growth seen in paroxysmal AF and persistent AF ablation procedure volumes?

What are the subsequent downstream impacts of rising AF ablation volumes on associated devices?

The availability of PFA devices is driving growth in the US market.

Which PFA catheters have been approved in the US? Which upcoming products are expected to gain approval in the US market?

How will market share dynamics shift with recent events occurring in this space?

Recent clinical guidelines will support the adoption of cardiac ablation procedures.

What changes have been made in the latest clinical guidelines regarding the use of cardiac ablation for treating cardiac arrhythmias?

How will the recent clinical guideline updates influence physicians’ opinions on ablation techniques for treating cardiac arrhythmia, particularly AF?

Positive clinical data will play a crucial role in driving the adoption of EP mapping and ablation devices, especially for premium-priced PFA catheters.

Which clinical trials have been recently conducted in this market?

What is the anticipated impact of these clinical trials on market dynamics?

How will the adoption of premium-priced PFA catheters be affected by the outcomes of recent clinical trials?